HitGen Inc.
https://www.hitgen.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HitGen Inc.
Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal
The deal marks the biggest out-licensing agreement ever for Chong Kun Dang, with the Swiss giant poised to explore the novel small molecule in various cardiovascular indications.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Company Information
- Industry
- Contract Research Organization-CRO
- Distributors
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
- Other Names / Subsidiaries
-
- HitGen Pharmaceuticals Inc., Vernalis (R&D) Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice